生物制剂在类风湿关节炎应用中的感染风险评估与选择

The selection and infections risk assessment of biological agents in the application of Rheumatoid Arthritis

近年来,生物制剂广泛应用于类风湿关节炎的治疗,极大地改善了患者疾病进展及预后,为治疗提供了新的有力武器。但随之而来罹患感染的风险亦不容忽视,已成为风湿界学者关注的热点问题。感染在不同类别生物制剂中发生率也不尽相同,临床医师应充分评估患者病情及感染风险,合理选择生物制剂,避免发生严重感染。本文就生物制剂在类风湿关节炎应用中的感染风险评估与选择作一综述。

In recent years, biological agents are widely used in the treatment of rheumatoid arthritis, and provide as a new powerful weapon for the great improvement of the prognosis and disease progression. However, treatment with biological agents increase the risk of infection couldn't be ignored, and became a hot issue in rheumatism field. The incidence of infection in different types of biological agents is not the same, so clinicians should fully assess the patient's condition and the risk of infection, rational use of biological agents to avoid the occurrence of severe infection.